<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674528</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0244</org_study_id>
    <secondary_id>2R01DK088925-06A1</secondary_id>
    <secondary_id>A539300</secondary_id>
    <secondary_id>SMPH/RADIOLOGY/RADIOLOGY</secondary_id>
    <secondary_id>Protocol Version 10/12/2021</secondary_id>
    <nct_id>NCT03674528</nct_id>
  </id_info>
  <brief_title>Technical Validation of MR Biomarkers of Obesity-Associated NAFLD</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Technical Validation of Magnetic Resonance Biomarkers of Obesity-Associated Non-Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this collaborative research program is to develop, validate and translate&#xD;
      advanced quantitative magnetic resonance (MR) biomarkers of obesity-associated non-alcoholic&#xD;
      fatty liver disease (NAFLD). This protocol represents the research plan for two distinct&#xD;
      phases. The first phase is an optimization phase. The second phase is designed to complete a&#xD;
      rigorous test of conventional and advanced MRE techniques. Complementary anthropometric,&#xD;
      laboratory, and MR measures will also be collected to characterize the cohort and identify&#xD;
      factors that affect MRE performance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term objective of this research is to improve the health of the millions of&#xD;
      Americans with or at risk for NAFLD, the most common chronic liver disease and most rapidly&#xD;
      growing indication for liver transplantation in the United States. To achieve this objective,&#xD;
      an advanced MR-based imaging method will be used to measure liver &quot;stiffness&quot; which is an&#xD;
      early sign of disease. This technique has been previously developed and validated and ready&#xD;
      to be used for further research. This current protocol will extend previous work by&#xD;
      optimizing and validating advanced 2 dimensional and 3 dimensional-magnetic resonance&#xD;
      elastography (MRE) methods as non-invasive biomarkers of hepatic inflammation and fibrosis in&#xD;
      obese patients at risk for non-alcoholic steatohepatitis (NASH), the histologically more&#xD;
      aggressive subset of NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Optimization of MRE for 2 dimensional and 3 dimensional methods</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Optimize MRE wave-field generation in this subject population to maximize the area of invertible shear waves in the liver into interpretable shear stiffness maps.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Group</arm_group_label>
    <description>Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Elastography (MRE)</intervention_name>
    <description>The MRE scan will several breath holds and will take approximately 30 minutes to complete.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Patient Group</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.</description>
    <arm_group_label>Patient Group</arm_group_label>
    <other_name>Intraoperative Biopsy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Phase 1 participants will be healthy adults with a BMI of greater/equal to 35 kilograms per&#xD;
        meter squared.&#xD;
&#xD;
        Phase 2 participants must be eligible for weight loss surgery and willing to undergo a&#xD;
        liver biopsy procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Phase 1 and 2 participants)&#xD;
&#xD;
          -  Age of at least 18 years&#xD;
&#xD;
          -  Severely obese (BMI â‰¥ 35 kg/m2) patient&#xD;
&#xD;
        Inclusion Criteria (Phase 2 participants only)&#xD;
&#xD;
          -  Cleared for weight-loss surgery&#xD;
&#xD;
          -  Willing and able to complete all safety and follow-up procedures&#xD;
&#xD;
          -  Willing to allow for the banking of biological samples&#xD;
&#xD;
        Exclusion Criteria (Phase 1 and 2 participants)&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
&#xD;
          -  Girth or weight that exceeds scanner capacity&#xD;
&#xD;
          -  Women of childbearing potential that are pregnant or will be attempting to become&#xD;
             pregnant during the study duration.&#xD;
&#xD;
        Exclusion Criteria (Phase 2 participants only)&#xD;
&#xD;
          -  Known liver malignancies&#xD;
&#xD;
          -  Regular &amp; excessive alcohol consumption within 2 years prior to recruitment&#xD;
&#xD;
          -  Use of steatogenic or hepatotoxic drugs&#xD;
&#xD;
          -  Clinical or laboratory evidence of liver disease other than Nonalcoholic fatty liver&#xD;
             disease (NAFLD)/ Nonalcoholic steatohepatitis (NASH) (e.g. HCV Ab, HBV Ab,&#xD;
             ceruloplasmin)&#xD;
&#xD;
          -  The subject has increased bleeding risk (i.e., decreased platelets, von Willebrand&#xD;
             disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Reeder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gemma Gliori, MS</last_name>
    <phone>608-262-7269</phone>
    <email>radstudy@uwhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Hanson, BS</last_name>
    <phone>608-263-7421</phone>
    <email>radstudy@uwhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin, Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Gliori, MS</last_name>
      <phone>608-262-7269</phone>
      <email>radstudy@uwhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Hanson, BS</last_name>
      <phone>608-263-7421</phone>
      <email>radstudy@uwhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Reeder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>MRE</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Liver Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

